rolapitant (Varubi)

Indications

• prevention of delayed-phase nausea & vomiting in adults undergoing chemotherapy
  • intended to be taken in combination with other antiemetics Pharmkacokinetics:
• inhibits the CYP2D6

Adverse effects

• common
  • neutropenia, hiccups, anorexia, dizziness

Drug interactions

• may increase levels of drugs metabolized by CYP2D6
  • thioridazine

Mechanism of action

• substance P receptor antagonist

More general terms

• anti-emetic

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10311306
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16203739
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=70687299
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71587824